Literature DB >> 26529633

De novo PIK3R1 gain-of-function with recurrent sinopulmonary infections, long-lasting chronic CMV-lymphadenitis and microcephaly.

Michaela Kuhlen1, Andrea Hönscheid1, Loizos Loizou2, Schafiq Nabhani1, Ute Fischer1, Polina Stepensky3, Jörg Schaper4, Wolfram Klapper5, Meinolf Siepermann1, Friedhelm Schuster1, Roland Meisel1, Arndt Borkhardt6.   

Abstract

PIK3R1 (phosphoinositide-3-kinase, regulatory subunit 1) gain-of-function has recently been described in patients with recurrent sinopulmonary infections, chronic CMV-/EBV-infections, lymphoproliferation, and hypogammaglobulinemia. Here we report a 15-year-old boy with treatment refractory CMV lymphadenitis, severe combined immunodeficiency, microcephaly and a severe developmental defect of Th17 cells. To avoid poor outcome, hematopoietic stem cell transplantation (HSCT) was performed. Subsequently, whole exome sequencing revealed a de novo heterozygous G-to-C mutation (chr5: 5:67,589,663: G>C) at the splice donor site of the PIK3R1 gene. Our data suggest that PIK3R1 gain-of-function leads to developmental defects in helper and regulatory T-cell subsets, the latter expanding the immunological features of PIK3R1 gain-of-function. T-cell subsets play a critical role in the regulation of immune response against infectious agents and of autoimmunity and thus may be particularly accountable for the clinical phenotype of affected patients.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic CMV infection; Immunodeficiency; Lymphoproliferation; PIK3R1; TH17 cells

Mesh:

Substances:

Year:  2015        PMID: 26529633     DOI: 10.1016/j.clim.2015.10.008

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  11 in total

Review 1.  Immune Dysregulation and Disease Pathogenesis due to Activating Mutations in PIK3CD-the Goldilocks' Effect.

Authors:  Stuart G Tangye; Julia Bier; Anthony Lau; Tina Nguyen; Gulbu Uzel; Elissa K Deenick
Journal:  J Clin Immunol       Date:  2019-03-25       Impact factor: 8.317

2.  Control of CD4+ T Cell Differentiation and Function by PI3K Isoforms.

Authors:  Benjamin Cameron; Syed Aymaan Zaheer; Margarita Dominguez-Villar
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.737

Review 3.  Herpesviruses in the Activated Phosphatidylinositol-3-Kinase-δ Syndrome.

Authors:  Jeffrey I Cohen
Journal:  Front Immunol       Date:  2018-02-23       Impact factor: 7.561

Review 4.  Phosphoinositide-3-Kinase Signaling in Human Natural Killer Cells: New Insights from Primary Immunodeficiency.

Authors:  Emily M Mace
Journal:  Front Immunol       Date:  2018-03-07       Impact factor: 7.561

Review 5.  Bacille Calmette-Guerin Complications in Newly Described Primary Immunodeficiency Diseases: 2010-2017.

Authors:  Cristiane de Jesus Nunes-Santos; Sergio D Rosenzweig
Journal:  Front Immunol       Date:  2018-06-22       Impact factor: 7.561

Review 6.  PI3Kδ and primary immunodeficiencies.

Authors:  Carrie L Lucas; Anita Chandra; Sergey Nejentsev; Alison M Condliffe; Klaus Okkenhaug
Journal:  Nat Rev Immunol       Date:  2016-09-12       Impact factor: 53.106

Review 7.  Epstein-Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) Immunodeficiency.

Authors:  Jean-Marie Carpier; Carrie L Lucas
Journal:  Front Immunol       Date:  2018-01-16       Impact factor: 7.561

Review 8.  Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.

Authors:  Gillian L Dornan; John E Burke
Journal:  Front Immunol       Date:  2018-03-19       Impact factor: 7.561

Review 9.  Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.

Authors:  Alison M Condliffe; Anita Chandra
Journal:  Front Immunol       Date:  2018-03-05       Impact factor: 7.561

Review 10.  "Immune TOR-opathies," a Novel Disease Entity in Clinical Immunology.

Authors:  Sophie Jung; Laura Gámez-Díaz; Michele Proietti; Bodo Grimbacher
Journal:  Front Immunol       Date:  2018-05-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.